Literature DB >> 2707061

Diagnosis and characteristics of lone atrial fibrillation.

E Davidson1, Z Rotenberg, I Weinberger, J Fuchs, J Agmon.   

Abstract

Thirty-two patients with LAF were studied. Nineteen (59 percent) were male subjects. Mean age was 46.8 years. They were followed up for 2 to 16 years. On admission, most patients (94 percent) were symptomatic and had palpitations, nine had nonspecific chest pain, and five had syncope or near syncope. Left atrial size measured by echocardiography was less than 40 mm in all patients. During the follow-up period, only one patient had a complication, ie, cerebral embolism. We conclude that LAF may be regarded as a relatively benign form of AF. According to our study, one of its features is left atrial size not larger than 40 mm in echocardiography.

Entities:  

Mesh:

Year:  1989        PMID: 2707061     DOI: 10.1378/chest.95.5.1048

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  Recovery of atrial systolic function after pharmacological conversion of chronic atrial fibrillation to sinus rhythm: a Doppler echocardiographic study.

Authors:  A Jović; R Troskot
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

2.  Latent arterial hypertension in apparently lone atrial fibrillation.

Authors:  Demosthenes G Katritsis; Ioannis K Toumpoulis; Eleftherios Giazitzoglou; Socrates Korovesis; Ilias Karabinos; George Paxinos; Constantinos Zambartas; Constantine E Anagnostopoulos
Journal:  J Interv Card Electrophysiol       Date:  2005-09       Impact factor: 1.900

Review 3.  Atrial Septal Defect and Atrial Fibrillation: The Known and Unknown.

Authors:  George E Blake; Dhanunjaya Lakkireddy
Journal:  J Atr Fibrillation       Date:  2008-09-16

Review 4.  Challenges in the classification of atrial fibrillation.

Authors:  Steven A Lubitz; Emelia J Benjamin; Jeremy N Ruskin; Valentin Fuster; Patrick T Ellinor
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

5.  Familial idiopathic atrial fibrillation with bradyarrhythmia.

Authors:  H Bertram; T Paul; F Beyer; H C Kallfelz
Journal:  Eur J Pediatr       Date:  1996-01       Impact factor: 3.183

6.  Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation.

Authors:  Christian Mahnkopf; Troy J Badger; Nathan S Burgon; Marcos Daccarett; Thomas S Haslam; Christopher T Badger; Christopher J McGann; Nazem Akoum; Eugene Kholmovski; Rob S Macleod; Nassir F Marrouche
Journal:  Heart Rhythm       Date:  2010-07-01       Impact factor: 6.343

Review 7.  Lone atrial fibrillation: does it exist?

Authors:  D George Wyse; Isabelle C Van Gelder; Patrick T Ellinor; Alan S Go; Jonathan M Kalman; Sanjiv M Narayan; Stanley Nattel; Ulrich Schotten; Michiel Rienstra
Journal:  J Am Coll Cardiol       Date:  2014-02-12       Impact factor: 24.094

Review 8.  The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations.

Authors:  S Nattel; T Hadjis; M Talajic
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

9.  Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community.

Authors:  Steven A Lubitz; Carlee Moser; Lisa Sullivan; Michiel Rienstra; João D Fontes; Mark L Villalon; Manju Pai; David D McManus; Renate B Schnabel; Jared W Magnani; Xiaoyan Yin; Daniel Levy; Michael J Pencina; Martin G Larson; Patrick T Ellinor; Emelia J Benjamin
Journal:  J Am Heart Assoc       Date:  2013-09-03       Impact factor: 5.501

10.  Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study.

Authors:  Steven A Lubitz; Xiaoyan Yin; Michiel Rienstra; Renate B Schnabel; Allan J Walkey; Jared W Magnani; Faisal Rahman; David D McManus; Thomas M Tadros; Daniel Levy; Ramachandran S Vasan; Martin G Larson; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2015-03-13       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.